-
Study aim
-
To investigate the effects of Dexmedetomidine on the inflammatory factors in patients undergoing Total Abdominal Hysterectomy (TAH).
-
Design
-
Randomised, controlled, parallel group trial with blinded outcome assessment. Randomisation was centralised with simple randomization with random number tables.
-
Settings and conduct
-
Forty patients undergoing Total Abdominal Hysterectomy are randomly divided into control and intervention groups in Ahvaz Imam Khomeini hospital.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria are females candidate of Total Abdominal Hysterectomy, Age<65, Body mass index: 18 to 40 kg/m2, and the ASA grade I , II; The exclusion criteria are allergic reaction to Dexmedetomidine, history of Dexmedetomidine administration over the past week, history of heart, lung, liver, and kidney diseases, patients with neuromuscular disorders, patients with anemia or bleeding disorders, consumption of Alcohol, narcotic and Antipsychotic medications, and patients with diabetes.
-
Intervention groups
-
Forty patients are randomly divided into control and intervention groups (n=20 cases). In the Intervention group, immediately after the induction, Dexmedetomidine with a bolus dose of (1 μg/kg) is injected for 15 mins and then infusion is done with a dose of (0.5 μg/kg) until the end of surgery. In the control group, immediately after the induction, normal saline with a dose of (1 μg/kg) is injected for 15 minutes and then infusion is done with a dose of (0.5 μg/kg) until the end of surgery.
-
Main outcome variables
-
ESR, C- Reactive Protein, Leukocytosis and Blood Glucose is measured by blood test at 30 mins before anesthesia induction (pre-intervention), 1 hour after the start of surgery, immediately, 6 and 24 hours after the completion of the surgical operation. MAP and HR are recorded before intervention, after intubation, every 15 minutes until the end of the recovery period.